Danaher Appoints Julie Sawyer Montgomery as CEO Amid Masimo Integration and Q2 Strength

Danaher Corporation (NYSE: DHR) this week announced the appointment of Julie Sawyer Montgomery as President and Chief Executive Officer, effective October 1, 2026. She will succeed Rainer Blair, who will retire and serve as a senior advisor through March 31, 2027 to ensure a smooth leadership transition.

This leadership change follows Danaher’s early closing of its acquisition of Masimo in June and its strong second-quarter performance, highlighting the company’s ongoing evolution in the life sciences and diagnostics sectors. The new CEO will steer Danaher through the integration of Masimo and build on recent operational momentum.

Leadership Transition Details

The company’s board announced the change on August 3, 2026, officially naming Julie Sawyer Montgomery as incoming CEO. Rainer Blair, who spearheaded the transformation of Danaher into a focused life sciences and diagnostics leader, will step into an advisory role after transitioning from the CEO post. This structured succession allows for continuity in strategic execution amid organizational change.

Context: Masimo Integration and Q2 Performance

Earlier this year, Danaher finalized its $9.8 billion cash acquisition of Masimo, a provider of advanced monitoring technologies, integrating it into its Diagnostics segment. While no material contribution from Masimo was expected in Q2, management plans to incorporate the acquired business into its full-year outlook soon.

On July 21, 2026, Danaher reported robust Q2 results—net earnings of $870 million, or $1.23 per diluted share, up 60% year-over-year, and non-GAAP adjusted EPS of $1.94 (up 8%). Revenue rose 5.5% to approximately $6.3 billion, with core revenue growth of 3%, and core revenue excluding respiratory testing at 4.5%. Operating cash flow reached $1.5 billion, and non-GAAP free cash flow hit $1.3 billion. The early closing of the Masimo deal enabled an upward revision of full-year adjusted EPS guidance.

Implications for Investors

The CEO transition positions Danaher to navigate its next phase of growth. Montgomery inherits leadership during a pivotal integration of Masimo, bolstered by recent financial strength. Investors willlikely monitor how she manages synergies from the acquisition, maintains core sales momentum—particularly outside respiratory testing—and leverages the Danaher Business System under her leadership.

As of August 24, 2026, Danaher shares were trading at $215.11, down 1.47% on the day.